Dash Bio

Dash Bio

Dash Bio develops an automated bioanalysis platform aimed at improving drug discovery processes. The company targets pharmaceutical companies and aims to reduce turnaround times for preclinical results through its innovative technology. This funding round will help expand its laboratory capacity and commercial operations.

Total raised
$30M
tracked to date
Latest round
Series A
Aug 3, 2026
Known investors
3
led by Oak HC/FT
Press coverage
2
outlets tracked

Is this your company?

Claim this profile to get matched with investors who fund Health startups in United States.

Claim this profile →

🏆 Featured in Datapile’s Q3 2026 USA Funding Report

Read the Q3 2026 USA report →
Add this badge to your site
<a href="https://datapile.co/reports/q3-2026-usa-startup-funding" target="_blank" rel="noopener" style="display:inline-flex;align-items:center;gap:8px;padding:9px 16px;border-radius:9999px;background:#0B1224;color:#ffffff;font:600 13px/1.2 -apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,Arial,sans-serif;text-decoration:none;border:1px solid #7C5CFF"><span style="display:inline-block;width:11px;height:11px;border-radius:3px;background:#7C5CFF"></span>Featured in Datapile&rsquo;s Q3 2026 USA Funding Report</a>

Funding history

  1. 1
    $30MSeries AAug 3, 2026

    Led by Oak HC/FT

    Announcement ↗

Founder

Dave Johnson
Dave Johnson
Co-founder & CEO

Investors in Dash Bio

Backers from this company's tracked funding rounds.

Dash Bio in the news

Coverage of this company's funding, tracked by Datapile.

More Health companies

Recently funded startups in the same category.

Related on Datapile